Bone Biologics Corp

During the three months ended December 31, 2025, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

On February 23, 2026, the Board of Directors determined that its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) will be held on August 11, 2026. The 2026 Annual Meeting date, the record date for the 2026 Annual Meeting and detailed information regarding the proposals to be presented at the 2026 Annual Meeting will be set forth in our Definitive Proxy Statement on Schedule 14A to be filed with the SEC. Since the 2026 Annual Meeting will take place more than 60 days after the anniversary of our last annual meeting of stockholders, the due dates for the submission of any qualified stockholder proposal or qualified stockholder nomination under applicable SEC rules and our Bylaws, as amended, listed in our Definitive Proxy Statement on Schedule 14A for our last annual meeting of stockholders, filed with the SEC on April 23, 2025, are no longer applicable. Such nominations or proposals are now due to be received by the Company no later than 90 calendar days prior to the 2026 Annual Meeting, or May 13, 2026, and must comply with all of the applicable requirements set forth in the rules. Stockholder proposals and director nominations should be mailed to the following address: Bone Biologics Corporation, Attention: Corporate Secretary, 2 Burlington Woods Drive, Suite 100, Burlington, MA 01803